TomoTherapy — Merger or Acquisition (March 2011)
23 slides from TomoTherapy's merger presentation, Mar 7, 2011
Slide 1: Creating the Premier Radiation Oncology Company
Creating the Premier Radiation Oncology Company
Slide 2: Forward-looking Statement Safe Harbor Statement
Forward-looking Statement Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry and the transaction between Accuray and TomoTherapy. Except for the historical inform
Slide 3: Agenda
Agenda Welcome Tom Rathjen Deal Summary Euan Thomson Corporate and Product Overview Accuray Overview (Euan Thomson) TomoTherapy Overview (Fred Robertson) Financial Profile Derek Bertocci Executive Summary Euan Thomson Q&A All
Slide 4: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialty Significant increase in global presence Financial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 5: Deal Summary
Deal Summary
Slide 6: Deal Terms
Deal Terms TomoTherapy shareholders to receive $4.80 per share* in cash and stock $3.15 in cash 0.1648 shares of Accuray stock ($1.65) Expected to be accretive to Accuray’s EPS in its fiscal year beginning July 1, 2012 Approved by both companies’ Board of Directors Anticipated to close in Q2 or earl
Slide 7: Corporate and Product Overview
Corporate and Product Overview
Slide 8: Accuray Incorporated
Accuray Incorporated 200+ systems installed 100,000+ patients treated 75+ issued patents *as of December 31, 2010
Slide 9: Accuray Corporate and Product Strategy
Accuray Corporate and Product Strategy CYBERKNIFE® ROBOTIC RADIOSURGERY SYSTEM Gold standard for Full Body Radiosurgery Unique image-guided robotic system with tumor and patient tracking capabilities Unsurpassed accuracy and three dimensional treatment delivery ACCURAY INCORPORATED Created and build
Slide 10: Accuray Record of Achievement
Accuray Record of Achievement Consistent record of technology innovation Regular upgrades support premium service programs New CyberKnife® platforms support stronger pricing Proven ability to drive market acceptance New products New clinical capabilities Profitability Product gross profit margin (>6
Slide 11: TomoTherapy Incorporated
TomoTherapy Incorporated Data provided by TomoTherapy 350 systems** 110,000+ patients treated 130+ issued patents **Shipped and/or installed as of February 17, 2011 *as of December 31, 2010
Slide 12: TomoTherapy Corporate and Product Strategy
TomoTherapy Corporate and Product Strategy TOMOTHERAPY® PLATFORM Daily CT guidance capabilities Unique helical delivery of IMRT Highly conformal dose distributions for simple and complex target volumes Enhanced platform versatility with TomoDirect™, TomoHD™ and TomoMobile™ TOMOTHERAPY INCORPORATED C
Slide 13: Financial Profile
Financial Profile
Slide 14: Keys to Financial Success of Acquisition
Keys to Financial Success of Acquisition Product Revenue: Maintain / Grow Best in class IMRT technology Profitable product revenue Continue growth in orders and revenue seen in CY 2010 Service: Turn From Loss to Profit Improve product reliability Reduce cost of service Cost Synergies: Reduce Operati
Slide 15: Product Revenue
Product Revenue Customer Relationships Significantly larger sales force Enhanced and more frequent customer contacts Greater Global Presence Direct service opportunities Direct sales opportunities in select countries Larger product portfolio More opportunities for customer contact R&D (future produc
Slide 16: Service Actions to Turn Profitable
Service Actions to Turn Profitable Fast Track Program (quarter ended December 31, 2010) Upgrade specific systems with high service costs TomoTherapy Plan: Design, Serviceability, Training Design changes to enhance reliability and serviceability Revise procedures and training in manufacturing and ser
Slide 17: Cost Synergies
Cost Synergies Examples Reduced G&A Expenses Public Company “overhead” e.g. Audit fees, SEC filings Corporate management duplication Marketing Expense Trade show attendance Professional membership fees Users’ events Expected Gross Operating Expense Synergies Approximately $25M per year by year two
Slide 18: Summary Corporate Metrics
Summary Corporate Metrics Metric Accuray TomoTherapy Revenue (CY2010) $206.1M $195.4M Net Income (CY2010) $6.8M ($29.9M) Expected Gross Operational Synergies Approx. $25M per year Product Backlog (Dec. 31, 2010) $170M* $133M** Installed Base 222 (12/31/10) 350*** (2/17/11) *Based on Accuray backlog
Slide 19: Executive Summary
Executive Summary
Slide 20: Increased Global Presence
Increased Global Presence Worldwide Install Base 572 Systems Installed** Worldwide Accuray TomoTherapy Americas EIMEA Japan APAC Accuray Post Transaction 222 Systems Installed* 350 Systems Installed** *Installed as of December 31, 2010 **Shipped and/or installed as of February 17, 2011
Slide 21: Strategic Rationale
Strategic Rationale Complementary patient populations, treated by the same medical specialty Significant increase in global presence Financial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company
Slide 22: Q&A
Q&A
Slide 23: Creating the Premier Radiation Oncology Company
Creating the Premier Radiation Oncology Company